Item 2. Properties
Item 2. Properties.
Our manufacturing facilities are located in Rancho Cucamonga and South El Monte, California; Canton, Massachusetts; Éragny-sur-Epte, France; and Nanjing, China. We own or lease a total of 68 buildings at six locations in the U.S., France and China, that comprise 2.4 million square feet of manufacturing, research and development, distribution, packaging, laboratory, office and warehouse space. Our facilities are regularly inspected by the FDA in connection with our product approvals, and we believe that all of our facilities are being operated in material compliance with the FDA’s cGMP regulations.
We continue to expand our facility in Nanjing, China and expect further significant investment.
The following table provides a summary of our owned properties as of December 31, 2024:
Aggregate
Facility Size
Location
(in square feet)
Primary Use
Rancho Cucamonga, CA
267,674
Headquarters, research and development, laboratories, manufacturing, packaging, warehousing and administrative offices
Éragny-sur-Epte, France
251,983
Manufacturing, laboratories, warehousing and administrative offices
Canton, MA
216,590
Manufacturing, packaging, warehousing, distribution and administrative offices
Nanjing, China
1,084,078
Manufacturing, procurement, research and development, warehousing, and administrative offices
Chino, CA
57,968
Research and development, and laboratories
South El Monte, CA
21,200
Manufacturing
The properties leased by us have expiration dates ranging from 2025 to 2034 (including certain renewal options). The following table provides a summary of our leased properties:
Aggregate
Facility Size
Location
(in square feet)
Primary Use
Rancho Cucamonga, CA
191,180
Warehousing, distribution and administrative offices
South El Monte, CA
343,413
Manufacturing, packaging, warehousing, distribution and administrative offices
We believe that our current manufacturing capacity is adequate for the near term. However, we are planning to increase capacity at our plant in Rancho Cucamonga, CA which should allow us to eventually quadruple the number of units produced at this facility. We are also increasing the capacity of our inhalation facility in Canton, MA and our insulin API production facility at ANP. We have in the past approached capacity at one of our facilities largely as a result of the
79
Table of Contents
FDA’s request that we reintroduce certain previously discontinued products to help cope with a nationwide shortage of these products. We believe that these capacity issues have been ameliorated as a result of certain other manufacturers re-entering the market and increasing the production of the products that were subject to the shortage.